Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21448719 | 0.89 | KCNJ1 (0.43) | KCNJ1KCNH2TDP1SIGMAR1KDM4E | |
| SCHEMBL17986179 | 0.84 | KCNJ1 (0.50) | KCNJ1KCNH2SIGMAR1HRH3KDM4E | |
| SCHEMBL8657520 | 0.84 | KCNJ1 (0.50) | KCNJ1KCNH2SIGMAR1HRH3KDM4E | |
| SCHEMBL17986050 | 0.83 | KCNJ1 (0.46) | KCNJ1KCNH2TDP1HRH3KDM4E | |
| SCHEMBL8715859 | 0.82 | KCNJ1 (0.77) | KCNJ1KCNH2SIGMAR1HRH3 | |
| SCHEMBL8509511 | 0.82 | KCNJ1 (0.77) | KCNJ1KCNH2SIGMAR1HRH3 | |
| SCHEMBL7158186 | 0.81 | PRMT5 (0.49) | KCNJ1KCNH2TDP1SIGMAR1KDM4E | |
| SCHEMBL17985899 | 0.80 | KCNJ1 (0.50) | KCNJ1KCNH2SIGMAR1HRH3KDM4E | |
| SCHEMBL17985929 | 0.80 | KCNJ1 (0.56) | KCNJ1KCNH2SIGMAR1HRH3KDM4E | |
| SCHEMBL17986054 | 0.80 | KCNJ1 (0.74) | KCNJ1KCNH2SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842893-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10441669-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20160235870-A1 | MULTIFUNCTIONAL CHELATORS, COMPLEXES, AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160235870-A1 | MULTIFUNCTIONAL CHELATORS, COMPLEXES, AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842893-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | FECH, SLC40A1, TFRC | KCNJ1 3900/4885KCNH2 4384/4885TDP1 1161/4885 |
| US-20160235870-A1 | MULTIFUNCTIONAL CHELATORS, COMPLEXES, AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | FECH, SLC40A1, TFRC | KCNJ1 3900/4885KCNH2 4384/4885TDP1 1161/4885 |
| US-10441669-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | FECH, SLC40A1, TFRC | KCNJ1 3900/4885KCNH2 4384/4885TDP1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.